1. Positioning therapies in ulcerative colitis;Danese S;Clin Gastroenterol Hepatol,2020
2. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. (2015). https.//www.nice.org.uk/guidance/ta329/chapter/1-Guidance.
3. Vedolizumab for treating moderately to severely active ulcerative colitis. (2015). https.//www.nice.org.uk/guidance/TA342/chapter/1-Guidance.
4. Ustekinumab for treating moderately to severely active ulcerative colitis. (2020). https.//www.nice.org.uk/guidance/TA633/chapter/1-Recommendations.
5. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease;Paramsothy S;Mucosal Immunol,2018